Author:
Bano Safia,Nawaz Ahmad,Numan Ahsan,Hassan Muhammad Aarish,Shafique Muhammad Bilal Ahmad
Abstract
Linezolid is a second-line medication used to treat tuberculosis that has become resistant to multiple drugs. Linezolid has been shown to be effective in treating drug-resistant TB. However, long-term therapy is hampered by the related side effects, such as ocular and peripheral neuropathy. We recently encountered a 32-year-old male undergoing linezolid therapy for 12 months for multidrug-resistant tuberculosis who presented with progressive painless visual impairment and peripheral neuropathy symptoms in lower limbs as well as ataxic gait. Nerve conduction study findings of length-dependent axonal sensory polyneuropathy with bilateral optic neuropathy evident on fundoscopy suggested a case of toxic neuropathy. Following the termination of linezolid, follow-up visits revealed an improvement in visual symptoms. While there has been no discernible improvement or deterioration of peripheral neuropathy. In a developing country like Pakistan, where the rising number of cases of multidrug-resistant tuberculosis and its management is a major problem, physicians should be made aware of linezolid induced neuropathy so that close follow-up sessions for patients on long-term linezolid therapy can be arranged to avoid serious neurological consequences.
Subject
Neurology (clinical),Neurology
Reference19 articles.
1. Global Tuberculosis Report.2018
2. Target regimen profiles for treatment of tuberculosis: a WHO document;Lienhardt;Eur Respir J,2017
3. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis.
4. Linezolid-induced optic neuropathy;Karuppannasamy;Indian J Ophthalmol.,2014
5. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome;Narita;Pharmacotherapy.,2007
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献